{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:45:58Z","timestamp":1776746758107,"version":"3.51.2"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Psoriasis is a complex chronic inflammatory skin disease. While typical cases are often diagnosed based on clinical features, achieving objective assessment of disease activity and precise early-stage identification remains a clinical focus. This study aims to evaluate the diagnostic value of monocytes (MONO), Orosomucoid-1 (ORM1), Orosomucoid-2 (ORM2), and Alpha-1-acid glycoprotein (AGP), and to develop a nomogram for the objective and early identification of psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective case-control study included 140 participants, comprising 70 patients with psoriasis confirmed by the dermatology department and 70 healthy individuals who underwent routine health examinations during the same period. Demographic, clinical, and laboratory data (including MONO, ORM1, ORM2, and AGP) were collected for all participants. Potential risk factors were initially screened using univariate Logistic regression, followed by feature selection via the combination of Lasso regression and Boruta algorithm to identify features with the highest predictive value. Restricted cubic spline (RCS) plots were utilized to visually illustrate the non-linear associations between the selected variables and the risk of psoriasis onset. Finally, the selected features were incorporated into a multivariate Logistic regression model to determine the independent risk factors, and a diagnostic nomogram was constructed accordingly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Based on the results of univariate analysis, LASSO regression and Boruta algorithm, we ultimately selected four key variables, namely MONO, ORM1, ORM2 and AGP, for the construction of the subsequent multivariate diagnostic model. The calibration curve of the model showed that the actual probability was highly consistent with the predicted probability, indicating that the model had good calibration performance. The receiver operating characteristic (ROC) curve indicated that the overall predictive ability of the model was excellent, with an area under curve (AUC) of 0.888 (95% CI: 0.835\u20130.941). In addition, the ROC curves of each variable analyzed separately showed that ORM2 (AUC = 0.777), ORM1 (AUC = 0.720), MONO (AUC = 0.638) and AGP (AUC = 0.673) all had different degrees of predictive ability for the risk of psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The novel biomarker combinations with stable and high expression in the early stage have shown great potential in the research of psoriasis. These research results should be applied to clinical.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1798926","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:22:16Z","timestamp":1776745336000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification and validation of a nomogram for psoriasis diagnosis: a novel biomarker combination with stable high expression in the early stage"],"prefix":"10.3389","volume":"13","author":[{"given":"Juanli","family":"Liu","sequence":"first","affiliation":[{"name":"Binhai County People\u2019s Hospital, Yancheng","place":["Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingqing","family":"Hu","sequence":"additional","affiliation":[{"name":"Binhai County People\u2019s Hospital, Yancheng","place":["Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianjin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Binhai County People\u2019s Hospital, Yancheng","place":["Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renshan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Binhai County People\u2019s Hospital, Yancheng","place":["Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study.","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"B2","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2147\/CCID.S352654","article-title":"Epidemiology and cutaneous manifestations of psoriasis in Saudi Arabia: a narrative review.","volume":"15","author":"Alzeer","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/1346-8138.15803","article-title":"Epidemiological survey of the psoriasis patients in the Japanese Society for Psoriasis Research from 2013 to 2018.","volume":"48","author":"Kamiya","year":"2021","journal-title":"J Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"541","DOI":"10.20344\/amp.19048","article-title":"Epidemiology of Psoriasis in Portugal: a population-based study.","volume":"36","author":"Torres","year":"2023","journal-title":"Acta Med Port"},{"key":"B5","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3390\/life12040501","article-title":"Biomarkers in oral fluids as diagnostic tool for psoriasis.","volume":"12","author":"Jim\u00e9nez","year":"2022","journal-title":"Life"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.3390\/biomedicines13071763","article-title":"Integrated multi-omics profiling reveals that highly pyroptotic MDMs contribute to psoriasis progression through CXCL16.","volume":"13","author":"Jin","year":"2025","journal-title":"Biomedicines"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1021\/pr500146y","article-title":"The role and importance of glycosylation of acute phase proteins with focus on alpha-1 antitrypsin in acute and chronic inflammatory conditions.","volume":"13","author":"McCarthy","year":"2014","journal-title":"J Proteome Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1007\/s13555-023-00992-2","article-title":"Tumor Necrosis Factor (TNF) \u03b1, Endothelin (ET) 1 and \u03b11-Acid Glycoprotein (AGP) as potential urine and serum markers of metabolic complications in psoriasis?","volume":"13","author":"Nowowiejska","year":"2023","journal-title":"Dermatol Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"831","DOI":"10.2147\/TCRM.S197633","article-title":"Urinary orosomucoid: a new marker of cardiovascular risk in psoriatic patients?","volume":"15","author":"N\u00e9meth","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.7150\/ijms.25687","article-title":"Urinary orosomucoid a potential marker of inflammation in psoriasis.","volume":"15","author":"Kust\u00e1n","year":"2018","journal-title":"Int J Med Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"7306","DOI":"10.1097\/MS9.0000000000003871","article-title":"Monocyte-to-lymphocyte ratio as a predictive marker for breast cancer treatment outcomes: a narrative review.","volume":"87","author":"Obeagu","year":"2025","journal-title":"Ann Med Surg"},{"key":"B12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/life14010114","article-title":"Impact of blood-count-derived inflammatory markers in psoriatic disease progression.","volume":"14","author":"Tiuc\u0103","year":"2024","journal-title":"Life"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1323174","DOI":"10.3389\/fimmu.2024.1323174","article-title":"Association between systemic immune inflammation index, systemic inflammation response index and adult psoriasis: evidence from NHANES.","volume":"15","author":"Ma","year":"2024","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e41715","DOI":"10.1097\/MD.0000000000041715","article-title":"Pan-immune inflammation value and systemic inflammatory index as a measure of systemic inflammation in patients with psoriasis: a retrospective study.","volume":"104","author":"Basar Kilic","year":"2025","journal-title":"Medicine"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","article-title":"Definition of treatment goals for moderate to severe psoriasis: a European consensus.","volume":"303","author":"Mrowietz","year":"2011","journal-title":"Arch Dermatol Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations.","volume":"34","author":"Nast","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1089\/adt.2023.014","article-title":"Psoriasis: striving for potential biomarkers.","volume":"21","author":"Dan","year":"2023","journal-title":"Assay Drug Dev Technol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1007\/s10753-025-02271-y","article-title":"NLRP3-inflammasome related genes as emerging biomarkers and therapeutic targets in psoriasis.","volume":"48","author":"Shi","year":"2025","journal-title":"Inflammation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e13822","DOI":"10.1111\/srt.13822","article-title":"Metagenomics reveals unique gut mycobiome biomarkers in psoriasis.","volume":"30","author":"Wang","year":"2024","journal-title":"Skin Res Technol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2346282","DOI":"10.1080\/09546634.2024.2346282","article-title":"Bibliometric analysis and description of research trends in the treatment of psoriasis with biologic agents in the past two decades (2004-2023).","volume":"35","author":"Wang","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.3389\/fimmu.2020.01432","article-title":"Quantitative proteomic profile of psoriatic epidermis identifies OAS2 as a novel biomarker for disease activity.","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.cyto.2014.12.014","article-title":"Cytokines in psoriasis.","volume":"73","author":"Baliwag","year":"2015","journal-title":"Cytokine"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.4049\/jimmunol.1402307","article-title":"Chronic psoriatic skin inflammation leads to increased monocyte adhesion and aggregation.","volume":"195","author":"Golden","year":"2015","journal-title":"J Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1619490","DOI":"10.3389\/fimmu.2025.1619490","article-title":"Exploring immune-inflammation markers in psoriasis prediction using advanced machine learning algorithms.","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4149\/BLL_2018_134","article-title":"Can alpha-1-acid glycoprotein affect the outcome of treatment in a cancer patient?","volume":"120","author":"Pitekova","year":"2019","journal-title":"Bratisl Lek Listy"},{"key":"B26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1051\/vetres:2008027","article-title":"Bovine alpha-1 acid glycoprotein can reduce the chemotaxis of bovine monocytes and modulate CD18 expression.","volume":"39","author":"Lecchi","year":"2008","journal-title":"Vet Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.3389\/fimmu.2020.02112","article-title":"Urinary proteomics identifying novel biomarkers for the diagnosis of adult-onset Still\u2019s disease.","volume":"11","author":"Sun","year":"2020","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s13105-015-0389-9","article-title":"Orosomucoid, an acute response protein with multiple modulating activities.","volume":"71","author":"Luo","year":"2015","journal-title":"J Physiol Biochem"},{"key":"B29","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000154269","article-title":"Orosomucoid types in allergic contact dermatitis.","volume":"45","author":"Fan","year":"1995","journal-title":"Hum Hered"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1798926\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:22:16Z","timestamp":1776745336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1798926\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":29,"alternative-id":["10.3389\/fmed.2026.1798926"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1798926","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"article-number":"1798926"}}